IL-17 regulates adipogenesis, glucose homeostasis, and obesity

LA Zúñiga, WJ Shen, B Joyce-Shaikh… - The Journal of …, 2010 - journals.aai.org
LA Zúñiga, WJ Shen, B Joyce-Shaikh, EA Pyatnova, AG Richards, C Thom, SM Andrade…
The Journal of Immunology, 2010journals.aai.org
Inflammatory mediators have the potential to impact a surprising range of diseases,
including obesity and its associated metabolic syndrome. In this paper, we show that the
proinflammatory cytokine IL-17 inhibits adipogenesis, moderates adipose tissue (AT)
accumulation, and regulates glucose metabolism in mice. IL-17 deficiency enhances diet-
induced obesity in mice and accelerates AT accumulation even in mice fed a low-fat diet. In
addition to potential systemic effects, IL-17 is expressed locally in AT by leukocytes …
Abstract
Inflammatory mediators have the potential to impact a surprising range of diseases, including obesity and its associated metabolic syndrome. In this paper, we show that the proinflammatory cytokine IL-17 inhibits adipogenesis, moderates adipose tissue (AT) accumulation, and regulates glucose metabolism in mice. IL-17 deficiency enhances diet-induced obesity in mice and accelerates AT accumulation even in mice fed a low-fat diet. In addition to potential systemic effects, IL-17 is expressed locally in AT by leukocytes, predominantly by γδ T cells. IL-17 suppresses adipocyte differentiation from mouse-derived 3T3-L1 preadipocytes in vitro, and inhibits expression of genes encoding proadipogenic transcription factors, adipokines, and molecules involved in lipid and glucose metabolism. IL-17 also acts on differentiated adipocytes, impairing glucose uptake, and young IL-17–deficient mice show enhanced glucose tolerance and insulin sensitivity. Our findings implicate IL-17 as a negative regulator of adipogenesis and glucose metabolism in mice, and show that it delays the development of obesity.
journals.aai.org